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Elevated glucose concentrations (\>3.5 mmol/l) normally suppress the release of glucagon from pancreatic alpha cells; dysregulation of this process is a feature of type 1 and type 2 diabetes \[[@CR1], [@CR2]\]. Both direct \[[@CR3]\] and indirect \[[@CR4]\] effects of glucose on the release of glucagon have been described. Whereas the latter appear to involve the release of secretory products, including insulin \[[@CR3], [@CR5]\], gamma-aminobutyric acid \[[@CR6]--[@CR8]\] or zinc ions \[[@CR4], [@CR9]\] from neighbouring beta cells, as well as somatostatin from delta cells \[[@CR10], [@CR11]\], the signalling events involved in the direct sensing of glucose are more controversial \[[@CR12]\]. These may involve enhanced metabolism of glucose and the closure of ATP-sensitive K^+^ channels, followed by limited membrane depolarisation \[[@CR13], [@CR14]\]. AMP-activated protein kinase (AMPK) appears also to be involved in the regulation of glucagon release \[[@CR15]\].

Per-arnt-sim (PAS) domain-containing protein kinases (PASKs) are related to AMPK and are common in prokaryotes. However, there is currently only one known mammalian counterpart \[[@CR16], [@CR17]\]. We \[[@CR18]\] and others \[[@CR19], [@CR20]\] have shown that PASK is important for energy sensing and maintenance of normal cellular energy balance in mammalian systems.

In pancreatic beta cells, PASK activity is regulated by glucose and is involved in the regulation of glucose-induced preproinsulin and pancreatic duodenum homeobox-1 (*Pdx1*) gene expression \[[@CR18], [@CR20]\]. Expression of the *Pask* gene in rodent islets and beta cell lines \[[@CR18], [@CR20]\] is also glucose-sensitive. Recently, PASK has been implicated in regulation of lipogenic gene expression \[[@CR19]\] and might, therefore, influence glucose signalling through lipid intermediates as proposed for glucose-induced insulin secretion \[[@CR21]\].

*Pask* homozygote knockout mice (*Pask*^−/−^), which are globally inactivated for *Pask*, have previously been reported to display lower plasma insulin levels than control littermates \[[@CR19]\], but normal glucose tolerance \[[@CR19], [@CR22]\], reflecting enhanced insulin sensitivity \[[@CR19]\]. Insulin secretion from *Pask*^−/−^ islets has variously been shown to be not different \[[@CR22]\] or lower \[[@CR19]\] than in control islets. It has also been previously reported that total insulin content and/or beta cell mass were not altered in *Pask*^−/−^ mice \[[@CR19], [@CR22]\]. However, data from these earlier studies are difficult to interpret for a number of reasons. In the first instance, total islet insulin was not always measured, making it difficult to evaluate the insulin secretory capacity of *Pask*^−/−^ islets. Moreover quantification of beta cell mass using pancreatic sections is prone to substantial variability \[[@CR19]\]. Due to these limitations \[[@CR19], [@CR22]\], the role of PASK in the regulation of pancreatic hormone release and glucose homeostasis remains to be clarified.

A recent report \[[@CR20]\] showed that inhibition of insulin gene expression by palmitate was reversed by *Pask* overexpression in MIN6 beta cells. The loss of PASK, and hence the loss of regulation by *Pdx1* and *Mafa* gene expression \[[@CR18]\], was proposed to be a mechanism by which insulin gene expression in the beta cell might be lost on exposure to palmitate \[[@CR20]\]. Thus, PASK appears to exert a protective effect in mature beta cells. Moreover, aberrant *PASK* expression and/or function may play a significant role in the development of diabetes and, interestingly, *Pask*^−/−^ mice develop glucose intolerance on a high-fat diet \[[@CR18]\].

Although glucose homeostasis reflects the release of multiple islet hormones in addition to insulin, there are currently no published data on the role of PASK in other islet cell types. The present study demonstrates that PASK is involved in the regulation of glucagon secretion from pancreatic alpha cells. We show that *PASK* expression is decreased in the islets of human type 2 diabetic patients and that *Pask* is at least as strongly expressed in highly purified mouse alpha cells as in beta cells. Silencing or ablation of *Pask* in clonal alpha cells or islets, respectively, drastically blunted the inhibition of glucagon secretion by glucose. Whereas the insulin content of PASK-deficient islets was dramatically reduced, the acute regulation of insulin secretion by glucose was normal. Thus, PASK regulates hormone release reciprocally from pancreatic alpha and beta cells. Given that dysregulation of insulin and glucagon secretion are characteristics of type 2 diabetes, we propose that PASK may be a potential drug target to modulate glucagon release in vivo.

Methods {#Sec2}
=======

**Materials** Adenoviruses encoding for human *PASK* have been previously described \[[@CR16]\]. All general chemicals and tissue culture reagents were purchased from Sigma (Poole, UK) or Invitrogen (Paisley, UK), unless otherwise stated in the text.

**Isolation and culture of islets** Studies on human islets were conducted with local ethics committee approval at all sites (Charing Cross Research Ethics Committee Ref. 07/H0711/114). Human islets were isolated as previously described in Oxford, UK \[[@CR23]\], or in Pisa, Italy \[[@CR24]\], and maintained in medium containing 11 mmol/l glucose for 10 days to allow the loss of exocrine tissue \[[@CR25]\]. Human type 2 diabetic donors were selected according to established criteria \[[@CR23], [@CR26]\]. Mouse pancreatic islets were isolated and cultured as described in \[[@CR3]\]. Alpha-TC1-9 cells (passage 35--45; American Type Culture Collection, Manassas, VA, USA) were cultured as previously described \[[@CR7]\].

**Laser capture microdissection and microarray analysis** These procedures were performed as described in Electronic supplementary material (ESM) Methods.

**RNA sequencing** We prepared 300 ng of total RNA with a kit (mRNA-Seq 8; Illumina, Little Chesterford, UK). For clustering and sequencing we used Illumina cluster generation and sequencing kits v4. 9pM were loaded to the flowcell (one sample per lane) and sequenced on a sequencer (GAIIx) with RTA software version 2.6 (Little Chesterford, UK). On average we obtained 28 million reads per lane, passing Illumina's quality filtering. Short reads (35 bp) were aligned to the mouse genome (Ensembl v54) using a mapping station (Genomatix) \[[@CR27]\] and to a database of known and potential splice junctions using Bowtie \[[@CR28]\]. Up to three mismatches and no insertions or deletions were allowed, and, on average, more than 85% of the reads in a sample could be mapped to the genome. Gene expression was measured as proposed by Mortazavi et al. \[[@CR29]\] and reads per kilobase per million (RPKM) values were computed for every gene.

*Mice Pask*^−/−^ mice (kindly provided by R. Wenger, Institute of Physiology and ZIHP, Zurich, Switzerland) \[[@CR30]\] were back-crossed for ten generations with C57BL/6 mice prior to use. Mice were housed with two to five animals per cage in a pathogen-free facility on a 12 h light--dark cycle with free access to standard mouse chow diet, unless otherwise stated. All in vivo procedures were performed in the Imperial College Central Biomedical Service in accordance with the Principles of Laboratory Care and the UK Home Office (Animals Scientific Procedures Act, 1986), and approved by the local ethics committee. Genotyping was performed as previously described \[[@CR30]\].

**Intraperitoneal glucose tolerance test** An intraperitoneal glucose tolerance test was performed on 8-week-old mice as described in \[[@CR31]\], at 09:00 hours on each experimental day.

**Measurement of total pancreatic insulin and glucagon** Pancreases were excised from 8-week-old mice and suspended in ice-cold acid--ethanol (75.0% ethanol--23.4% molecular grade water--1.5% HCl--0.1% Triton X-100, vol./vol.) prior to disruption by sonication (microsonicator; Misonix, Farmingdale, NY, USA) at 4°C. Total protein was measured by Bradford's assay \[[@CR32]\], and insulin and glucagon content were measured by radioimmunoassay (Linco, Watford, UK).

**Measurement of plasma glucagon** At 8 weeks of age mice were starved overnight prior to being killed by cervical dislocation. Blood (200 μl) was immediately removed by cardiac puncture. Plasma was collected using high-speed centrifugation (2,000 *g*, 5 min) in heparin-coated tubes (Microvette; Sarstedt, Leicester, UK) and plasma glucagon assessed by radioimmunoassay (Linco, Watford, UK).

**Manipulation of PASK content in alpha-TC1-9 cells and cultured islets of Langerhans** Alpha-TC1-9 cells and islets were infected with adenoviruses encoding for PASK or enhanced green fluorescent protein at a multiplicity of infection of 100 and cultured for 48 h prior to use. Alpha-TC1-9 cells were transfected with anti-*Pask* small interfering RNA (siRNA) or control siRNA (1 nmol/l) \[[@CR18]\]. Protein content was assessed by western (immuno-)blot analysis.

**Culture of E13.5 rat pancreatic epithelia** E13.5 rat pancreatic epithelia were isolated and cultured as previously described \[[@CR33]\]. Epithelia were cultured in the presence of anti-*Pask* siRNA or control siRNA \[[@CR18]\] (1 nmol/l) for 10 days prior to RNA isolation for real-time quantitative PCR analysis.

**Real-time quantitative PCR analysis** Highly purified primary mouse islet beta and alpha cells were obtained by fluorescence-activated cell sorting of transgenic mice expressing the fluorescent protein Venus selectively in the alpha cell under the preproglucagon promoter \[[@CR34], [@CR35]\]. RNA was extracted from alpha-TC1-9 cells and cultured rat E13.5 explants using Trizol (Invitrogen) according to the manufacturer's guidelines. Total RNA was subjected to DNAse treatment (Ambion, Warrington, UK), followed by cDNA conversion (high-capacity cDNA conversion kit; Applied Biosystems, Warrington, UK) and real-time quantitative PCR using SYBR green (Applied Biosystems) in a 7500 Real-Time PCR System (ABI, Warrington, UK).

**Western (immuno-)blot analysis** Western (immuno-)blot analysis was performed as previously described \[[@CR18]\].

**Statistical analysis** Data are the means ± SE for the number of observations indicated. Statistical significance and differences between means were assessed by Student's *t* test with Bonferroni correction for multiple analyses.

Results {#Sec3}
=======

**PASK gene expression is regulated by glucose in human pancreatic islets of Langerhans and is lowered in type 2 diabetes** We have previously shown that *Pask* mRNA and protein levels are increased by high glucose in rat islets and clonal MIN6 beta cells \[[@CR18]\]. Here, we first determined whether islet *PASK* expression may also be regulated by glucose or by diabetes in humans. Measured in human islets of Langerhans by quantitative PCR, *PASK* mRNA was elevated after 24 h culture at 11 mmol/l glucose (2.7 ± 0.2-fold vs culture at 3 mmol/l glucose \[means ± SE\]; Fig. [1a](#Fig1){ref-type="fig"}). Measured after culture at 11 mmol/l glucose, *PASK* gene expression was significantly lower in islets from patients with type 2 diabetes than in control islets (Fig. [1b](#Fig1){ref-type="fig"}). Fig. 1*PASK* expression is regulated by glucose in human islets and is lowered in type 2 diabetic islets. Real-time quantitative PCR on non-diabetic (**a**, **b**) or type 2 diabetic (T2D) (**b**) human islet RNA, following culture at the indicated glucose concentrations for 24 h (**a**) or at 11 mmol/l glucose (**b**); *n* = 3; \**p* \< 0.05, \*\**p* \< 0.01. **c***Pask* mRNA content in FACS-purified mouse alpha and beta cells; ^†^*p* = 0.07

mRNA expression data obtained using whole islets may be confounded by variable degrees of contamination with other pancreatic cell types, as well as by other factors. Therefore, we sought to further support the above results by using laser capture microdissection and array analysis to quantify mRNA levels selectively in beta cell-enriched samples \[[@CR26]\]. A clear tendency for decreased *PASK* expression in islets in type 2 diabetic pancreases vs controls was also observed using this approach (ESM Fig. [1](#MOESM1){ref-type=""}). In contrast, consistent changes in levels of the AMPK-alpha1 and -alpha2 subunit (encoded by *PRKAA1* and *PRKAA2*, respectively) were not observed with array data on samples obtained by laser capture microdissection. However, with quantitative PCR done on the same samples with enough RNA (10 vs 10), a small but statistically significant decrease in *PRKAA1* expression was apparent (18%; *p* \< 0.019), using *RPL32* as an internal control.

***Pask* is expressed in murine pancreatic beta and alpha cells** In the mouse, *Pask* mRNA has previously been shown to be most abundant in testes as well as in haemopoietic tissues including thymus and spleen \[[@CR30]\]. Levels in other tissues, including islets, are much lower \[[@CR30]\] (G. A. Rutter and G. Sun, unpublished observations). Indeed, the expression of *Pask* in adult mouse islets and its induction by glucose have recently been questioned, since expression in these cells of the *lacZ* gene, expressed in mice null for *Pask* alleles under the *Pask* promoter, was barely detectable by beta-Gal staining \[[@CR22]\]. By contrast, we have previously detected *Pask* mRNA in mouse islets and MIN6 cells \[[@CR18]\], data recently confirmed by others \[[@CR20]\]. Examined here in islets from mice on a mixed C57BL/6/sv129 background cultured at 11 mmol/l glucose, massive parallel sequencing (RNAseq) confirmed the presence of *Pask* mRNA at low but detectable levels, lying in the lower 30th percentile of all mRNAs at approximately 0.2 ± 0.3% (*n* = 3 female mice) of β-actin mRNA levels (ESM Fig. [2](#MOESM2){ref-type=""}).To determine in which cell types *Pask* was expressed in mouse islets, we next compared the expression of *Pask* mRNA in highly purified primary mouse alpha and beta cells (Fig. [1c](#Fig1){ref-type="fig"}). These were obtained by fluorescence-activated cell sorting of transgenic mice selectively expressing the fluorescent protein, Venus, in the alpha cell \[[@CR34], [@CR35]\] and by real-time quantitative PCR analysis. This approach confirmed the presence of *Pask* mRNA in both cell types and indicated that levels in purified alpha cells (1.45 ± 0.46% of beta-actin mRNA) tended to be higher than in beta cells (0.54 ± 0.044%; *n* = 3 preparations; *p* = 0.07 by two-tailed Student's *t* test).

**Pask^−/−^ mice display normal glucose tolerance but impaired plasma glucagon concentration** Given the greater expression of *Pask* in alpha than in beta cells and the dysregulation of glucagon secretion observed in type 2 diabetes, as reviewed by others \[[@CR2]\], we next analysed the potential contribution of this enzyme to the regulation of glucagon secretion using *Pask*^−/−^ mice. At 8 weeks of age, *Pask*^−/−^ male (Fig. [2a, c, e](#Fig2){ref-type="fig"}) and female (Fig. [2b, d](#Fig2){ref-type="fig"}) mice displayed 25 ± 5% higher plasma glucose levels after 16 h of fasting than wild-type littermate control mice, but normal glucose tolerance after intraperitoneal injection of the sugar (Fig. [2a--d](#Fig2){ref-type="fig"}). Measured after fasting, plasma glucagon was significantly higher in *Pask*^−/−^ male mice than in littermate controls (91 ± 5.4 vs 58 ± 3 pg/ml; Fig. [2e](#Fig2){ref-type="fig"}). Fig. 2*Pask*^−/−^ mice display higher fasted glucose levels than littermate controls. At 8 weeks of age, male (**a, c**) and female (**b, d**) *Pask*^*−/−*^ mice were starved for 16 h prior to an intraperitoneal glucose tolerance test (1 g glucose per kg body weight). **c**, **d** Blood glucose at 0 min, as indicated by dotted squares (**a**, **b**), for male and female mice, respectively. **e** Plasma glucagon concentrations from male mice following 16 h of fasting. *n* = 8--10 mice per group; \**p* \< 0.05, \*\**p* \< 0.01. Black squares and solid lines, *Pask*^*+/+*^, wild-type; rhombuses and dotted lines, *Pask*^+/−^, heterozygote; black triangles and dashed lines, *Pask*^−/−^, homozygous knockout

**Islets of Langerhans from Pask^−/−^ mice display impaired glucose-regulated glucagon secretion** We next examined whether the elevated plasma glucagon concentration was due to dysregulation of alpha cell function. Supporting this view, the inhibition of glucagon secretion in response to elevated glucose was impaired in islets from *Pask*^−/−^ mice (Fig. [3a](#Fig3){ref-type="fig"}). Thus, *Pask*^−/−^ islets, in which *Pask* gene expression was undetectable (Fig. [3e](#Fig3){ref-type="fig"}), secreted 2.04 ± 0.2-fold more glucagon at inhibitory (10 mmol/l) glucose concentrations than did islets from wild-type littermates (Fig. [3a](#Fig3){ref-type="fig"}), whereas release at stimulatory (0.5 mmol/l) glucose was unaltered. Interestingly, a slight inhibitory effect on glucagon secretion in *Pask*^−/−^ islets was still observed at 10 mmol/l glucose (Fig. [3a](#Fig3){ref-type="fig"}). Although glucose-stimulated insulin release when normalised to total islet insulin content was not affected by *Pask* deletion (Fig. [3b](#Fig3){ref-type="fig"}), the total amount of insulin per islet was lower (0.38 ± 0.3-fold) in *Pask*^−/−^ than in wild-type islets (Fig. [3d](#Fig3){ref-type="fig"}), i.e. the amount of insulin release was compromised in *Pask*^−/−^ islets, in agreement with published data \[[@CR19]\]. Fig. 3Islets from *Pask*^−/−^ mice display abnormal inhibition of glucagon secretion in response to glucose. **a** Glucagon and (**b**) insulin secretion in response to glucose was assessed in groups of ten mouse islets, as previously described \[[@CR7]\]. Data presented ar e% secreted hormone/total hormone content in 10 islets. White bars, islets exposed to 0.5 mmol/l glucose; black bars, islets exposed to 10 mmol/l glucose. **c** Total glucagon and (**d**) insulin from mouse islets of each genotype. *n* = 3 separate preparations of islets. **e** Total RNA was extracted from groups of 100 islets using Tri-reagent (Invitrogen) and gene expression analysed by real-time quantitative PCR analysis using SYBR-green (Applied Biosystems). Cyclophilin gene expression was used as the internal calibrator. *n* = 3 Nd, not detected; black bars, *Pask*^*+/+*^ wild-type islets; grey bars, *Pask*^+/−^ heterozygote islets; white bars, *Pask*^−/−^ homozygous knockout mice islets. \**p* \< 0.05, \*\**p* \< 0.01The expression of mouse preproinsulin 2 (*Ins2*) and *Pdx1* genes was strongly impaired in *Pask*^−/−^ mouse islets (Fig. [3e](#Fig3){ref-type="fig"}), as previously reported \[[@CR18], [@CR20]\]. Moreover, the insulin content of whole *Pask*^−/−^ mouse pancreases was 1.98 ± 0.3-fold lower than that of wild-type pancreases (67 ± 15 vs 133 ± 12 ng/mg protein for *Pask*^−/−^ and wild-type mice, respectively; *n* = 3 mice for each genotype). While glucagon protein content in *Pask*^−/−^ islets (Fig. [3c](#Fig3){ref-type="fig"}) was unaffected, preproglucagon (*Gcg*) gene expression was slightly but significantly increased, as was *Prkaa2* mRNA expression (Fig. [3e](#Fig3){ref-type="fig"}).

**Glucagon release is activated in the absence of Pask in alpha-TC1-9 cells** Since the above experiments using intact islets did not allow ready discrimination between an action of PASK cell-autonomously in the alpha cell and an effect mediated by changes in the release of beta cell-derived factors, we next explored the role of the enzyme in the clonal alpha-TC1-9 cell line \[[@CR3]\]. Culture of alpha-TC1-9 cells in the presence of an siRNA against *Pask* led to near complete ablation of *Pask* gene expression and protein content (Fig. [4a](#Fig4){ref-type="fig"}). Glucagon release from *Pask*-deficient alpha-TC1-9 cells at inhibitory (10 mmol/l) glucose concentrations was comparable to that observed in control cells at stimulatory (0.5 mmol/l) glucose concentrations (Fig. [4b](#Fig4){ref-type="fig"}). By contrast, addition of extracellular insulin (20 nmol/l) led to inhibition of glucagon secretion in control and *Pask*-silenced alpha-TC1-9 cells, indicating (1) the presence of distinct glucose and insulin signalling pathways in the alpha cell and (2) that the insulin signalling pathway in *Pask*-silenced alpha-TC1-9 cells was intact (Fig. [4b](#Fig4){ref-type="fig"}). Total glucagon protein content, as assessed by radioimmunoassay, was not different between alpha-TC1-9 cells treated with control or anti-*Pask* siRNA (data not shown). Fig. 4PASK silencing activates glucagon secretion in alpha-TC1-9 cells. **a** Transfection of alpha-TC1-9 cells with 1 nmol/l *Pask* siRNA led to decreased *Pask* expression and PASK protein content, as assessed by real-time quantitative PCR and western (immuno-)blot analysis. The migration of molecular weight markers (BioRad, Hemel Hempstead, UK) is indicated on the western (immuno-)blot. **b** Glucagon secretion in response to elevated glucose and insulin was assessed as described in Fig. [3](#Fig3){ref-type="fig"}, *n* = 3. Data presented are % secreted hormone/total hormone content per sample. White bars, transfected with control; grey bars, transfected with anti-*Pask* siRNA. \**p* \< 0.05, \*\**p* \< 0.01

**Glucagon release is inhibited by PASK overexpression in alpha-TC1-9 cells and human islets of Langerhans** The above findings indicated that PASK may be an inhibitor of glucagon release from alpha cells. To test this hypothesis, we next explored the impact of forced activation of the enzyme in these cells. Adenovirus-mediated overexpression of *PASK* in alpha-TC1-9 cells (Fig. [5a](#Fig5){ref-type="fig"}) led to inhibition of glucagon secretion at normally stimulatory (1 mmol/l) glucose concentrations (0.36 ± 0.1-fold vs control). Fig. 5Overexpression of PASK inhibits glucagon secretion in alpha-TC1-9 cells and human islets of Langerhans. **a** Alpha-TC1-9 cells were infected with adenovirus encoding for *PASK* (grey bars) or enhanced green fluorescent protein (EGFP; control virus, white bars) at multiplicity of infection of 100 and cultured for 24 h prior to glucagon secretion as described in Fig. [3](#Fig3){ref-type="fig"}, *n* = 3. **b** Human islets of Langerhans were infected with adenovirus for human *PASK* or EGFP at multiplicity of infection of 100 and cultured for 48 h prior to glucagon secretion assay \[[@CR3]\], *n* = 3. Data presented are % secreted hormone/total hormone content per sample. **c** Western (immuno-)blot analysis of protein extracts from alpha-TC1-9 cells and human pancreatic islets after 48 h transduction with adenoviruses encoding for PASK or EGFP. PASK protein content was normalised to tubulin protein content as assessed by densitometry using ImageJ (<http://rsbweb.nih.gov/ij/index.html>; *n* = 3). Representative images from at least three separate preparations of each are shown. \**p* \< 0.05, \*\**p* \< 0.01Similarly, overexpression of *PASK* in human islets of Langerhans (Fig. [5b](#Fig5){ref-type="fig"}) inhibited glucagon secretion at all glucose concentrations tested, while the stimulatory effects of KCl were largely maintained. Interestingly, there was still an apparent effect of glucose on glucagon secretion in human islets overexpressing *PASK* (Fig. [5b](#Fig5){ref-type="fig"}), consistent with a maintained effect on glucagon release mediated by beta cell-derived factors.

**Silencing of *Pask* gene expression in alpha-TC1-9 cells and E13.5 rat pancreatic epithelial explants causes increased AMPK-alpha2 and glucagon gene expression** In an effort to identify the mechanism(s) through which PASK may regulate glucagon secretion, we measured the expression of a number of potential target genes. *Pask* gene expression was inhibited in alpha-TC1-9 cells treated with a siRNA against *Pask* (Fig. [6](#Fig6){ref-type="fig"}). In line with the above findings in *Pask*^−/−^ mouse islets (Fig. [3e](#Fig3){ref-type="fig"}), preproglucagon (*Gcg*) gene expression was increased substantially by *Pask* ablation in alpha-TC1-9 cells (7.4 ± 1.3-fold vs control; Fig. [6a](#Fig6){ref-type="fig"}), although total glucagon protein content was unaltered (Fig. [2c](#Fig2){ref-type="fig"}), consistent with the relatively slow turnover of mature glucagon. *Prkaa2* (Fig. [6a](#Fig6){ref-type="fig"}), but not *Prkaa1* (data not shown) gene expression was also increased (4.3 ± 1.5-fold vs control) by *Pask* silencing. Fig. 6*Pask* silencing in alpha-TC1-9 cells leads to increased expression of *Gcg* and *Prkaa2*. Real-time quantitative PCR analysis, using SYBR green (Applied Biosystems), of RNA from alpha-TC1-9 cells treated with control or *Pask* siRNA, *n* = 3. Cyclophilin gene expression was used as the internal calibrator for real-time quantitative PCR. White bars, treated with control; grey bars, treated with anti-*Pask* siRNA. \*\**p* \< 0.01To determine whether the dysregulation of glucagon gene expression and release in *Pask*^*−/−*^ mice was due to a role of the enzyme in the development of pancreatic alpha and beta cells, we next examined the impact of *Pask* silencing in developing pancreatic epithelia. E13.5 rat pancreatic epithelial explants \[[@CR33]\], in which *Pask* gene expression was silenced with an anti-*Pask* siRNA, developed endocrine buds to an extent indistinguishable from that observed in explants treated with a control (scrambled) siRNA (ESM Fig. [3](#MOESM3){ref-type=""}). However, explants in which *Pask* was silenced displayed similar increases in *Gcg* and *Prkaa2* gene expression (ESM Fig. [3](#MOESM3){ref-type=""}) to those observed in alpha-TC1-9 cells (Fig. [6](#Fig6){ref-type="fig"}). Explants overexpressing *Pask* did not survive the 10 day culture period.
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The present data indicate that *PASK/Pask* is expressed in human and mouse pancreatic islets, respectively, and regulated by glucose. Moreover, in the mouse, *Pask* mRNA levels are at least as high in alpha cells as in beta cells. Correspondingly, we provide evidence that changes in *Pask* gene expression within the islet regulate both insulin content \[[@CR18], [@CR20]\] and glucagon release, i.e. that PASK mediates a 'high glucose' signal in alpha and beta cells. In the alpha cell, this might be achieved either via a cell-autonomous action on cellular activity and/or through changes in the release of beta cell-derived factors (Fig. [7](#Fig7){ref-type="fig"}). Either of these mechanisms are likely to modulate intracellular signalling within the alpha cell through changes in membrane excitability, levels of unbound Ca^2+^, cAMP, etc. Fig. 7Proposed mechanism for PASK action in alpha cells. Glucagon secretion is regulated by changes in extracellular glucose and other factors, including insulin and possibly other molecules released from pancreatic beta cells. We propose (dashed lines) that PASK may be involved in cell-autonomous regulation of glucagon secretion, possibly through the regulation of *Prkaa2* gene expression (AMPK-alpha2) (1) and/or an as yet unidentified pathway (2). PASK may also regulate glucagon secretion through its action on beta cell function and/or beta cell mass (3)

**PASK is expressed in pancreatic islets** An important finding of the present study is that *Pask* mRNA is clearly present in mouse islets maintained at permissive glucose concentrations (11 mmol/l), in contrast to a recent suggestion \[[@CR22]\]. These results and those from another recent publication \[[@CR20]\] support our own previous findings \[[@CR18]\]. We would stress, however, that the level of gene expression, at least at the mRNA level, was relatively low compared with tissues in which *Pask* is strongly expressed (notably in the testes) \[[@CR22]\], an observation that probably underlies the failure to detect significant expression using alternative approaches \[[@CR22]\].

**PASK regulates insulin and glucagon secretion** It has previously been shown that islet architecture and beta cell mass in *Pask*^−/−^ mice are intact \[[@CR19], [@CR22]\]. Thus, it was hypothesised in earlier studies that the observed decrease in insulin release may have been due to defective glucose-signalling in the beta cell \[[@CR19]\]. In contrast, our data show that glucose-regulated insulin secretion was intact in *Pask*^−/−^ islets (Fig. [3b](#Fig3){ref-type="fig"}), but that the insulin content of the islet (Fig. [3d](#Fig3){ref-type="fig"}) and pancreas (see Results section) were lowered by *Pask* deletion. This apparent discrepancy between the present and earlier \[[@CR19], [@CR22]\] studies may reflect differences in the genetic background, age and sex of the mice used. We would, however, note that *Pask*^−/−^ beta cell mass was previously assessed by immunohistochemical analysis of fixed pancreatic sections, which may be prone to error.Nevertheless, it was previously reported that plasma insulin content was compromised in *Pask*^−/−^ mice \[[@CR19]\], a result consistent with the present findings. In our hands, glucagon release from *Pask*^−/−^ mouse islets (Fig. [3a](#Fig3){ref-type="fig"}) and human islets in which *PASK* was overexpressed (Fig. [5b](#Fig5){ref-type="fig"}) still displayed some degree of glucose-responsiveness, even though this was markedly decreased compared with the control condition. We hypothesise that this 'residual' regulation of release may be due, at least in part, to the release of insulin or other factors (Zn^2+^, gamma-aminobutyric acid, etc.) from neighbouring pancreatic beta cells and is consistent with the maintained effect of exogenous insulin on glucagon release from alpha-TC1-9 cells (Fig. [4b](#Fig4){ref-type="fig"}).Close inspection of the data of Fig. [3a](#Fig3){ref-type="fig"} vs Fig. [4](#Fig4){ref-type="fig"} reveals that whereas loss of *Pask* enhanced glucagon secretion from islets only at high (inhibitory) glucose levels (Fig. [3a](#Fig3){ref-type="fig"}), stimulation of glucagon release was apparent at all glucose concentrations examined in alpha-TC1-9 cells (Fig. [4](#Fig4){ref-type="fig"}). The mechanisms responsible for this difference are unclear. However, we note that while insulin mRNA was present at low but detectable levels in control alpha-TC-1-9 cells (C~t~ values  ≥ 29; data not shown), silencing of *Pask* led to decreased insulin gene expression such that this was below the limit of detection. Hence an action of *Pask* silencing on endogenous insulin secretion from alpha-TC-1-9 cells, and thus loss of tonic inhibition of glucagon secretion by this hormone, may contribute to the above mechanisms. Further studies are needed to resolve this question.Interestingly, the increase in plasma glucagon levels measured after 16 h fasting in 8-week-old *Pask*^−/−^ mice was similar to that observed in alpha cell-specific insulin receptor knockout mice of the same age \[[@CR5]\]. We have previously shown that PASK activity is not regulated by insulin, but that PASK may regulate insulin gene expression in pancreatic beta cells \[[@CR18]\]. Thus, we propose that the regulation of insulin content by *Pask* is one of the mechanisms through which PASK may indirectly regulate glucagon release.

**A role for AMPK alpha2 downstream of PASK?** Our gene-expression studies revealed that expression of the catalytic subunit of another glucose-responsive fuel gauge, *Prkaa2* (encoding AMPK-alpha2), is upregulated when *Pask* gene expression is compromised (Fig. [6](#Fig6){ref-type="fig"}). This is an interesting observation, since AMPK activity has been shown to be glucose-responsive in pancreatic beta cells \[[@CR36]\] and to regulate insulin release \[[@CR37], [@CR38]\]; in addition, we have recently shown that activation of AMPK in the alpha cell stimulates glucagon secretion \[[@CR15]\]. However, as also observed here, *Prkaa2* mRNA levels are normally much lower (more than tenfold) than *Prkaa1* in purified mouse beta and alpha cells \[[@CR31]\], suggesting that the inappropriate activation of this isoform and an increase in AMPK activity in the nucleus (from which AMPK alpha1 is excluded in mature pancreatic endocrine cells) \[[@CR36]\] may impact on the transcription of key genes, including *Gcg*, to reprogram the alpha cell. Interestingly, induction of *Prkaa2* expression was also observed in E13.5 pancreatic epithelia \[[@CR33]\] in which *Pask* was silenced (Fig. [6c](#Fig6){ref-type="fig"}), indicating that defects during pancreatic development may contribute to the dysregulation of glucagon release in *Pask*^*−/−*^ mice.

**PASK may have a role in the pathophysiology of type 2 diabetes** The observation that pancreatic islets from patients with type 2 diabetes display lower *PASK* mRNA levels than islets from non-diabetic individuals (Fig. [1b](#Fig1){ref-type="fig"}) suggests that lowered PASK activity may contribute to decreased insulin release and to enhanced glucagon secretion in this condition \[[@CR1]\]. PASK may therefore represent a potential therapeutic target, the activation of which might favourably affect the secretion of both hormones in patients with type 2 diabetes.
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